Biotech | February 28, 2026
Synthekine teams up with Merck to test breakthrough lung cancer combo
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
If approved, DTX401 would be the first treatment to address the disease at its root cause
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Subscribe To Our Newsletter & Stay Updated
